Robotic Hysterectomy in India and UAE | Complete Patient Guide

• MEDICAL INDICATIONS (WHO IS ELIGIBLE):

• Symptomatic uterine fibroids (leiomyomata) causing menorrhagia, bulk symptoms, pelvic pressure, or urinary frequency, unresponsive to GnRH agonist therapy (e.g., leuprolide acetate) or levonorgestrel IUD

• Adenomyosis with debilitating dysmenorrhea and/or heavy menstrual bleeding, confirmed on MRI (junctional zone thickness >12 mm)

• Severe endometriosis (ASRM Stage III–IV) with rectovaginal nodules, hydrosalpinx, or recurrent ovarian endometriomas after medical failure

• Abnormal uterine bleeding (AUB) not controlled by tranexamic acid, combined oral contraceptives, or progestins, with endometrial hyperplasia with or without atypia

• Uterine or cervical malignancy (endometrial carcinoma FIGO Stage I–II; early-stage cervical cancer FIGO IB1–IIA) requiring surgical staging ± lymphadenectomy

• Symptomatic uterine prolapse (POP-Q Stage II–IV) in conjunction with pelvic floor repair

• Chronic pelvic pain attributable to confirmed uterine pathology after exhaustion of conservative therapy

• Patients who have completed childbearing and consent to permanent loss of fertility

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Transvaginal Ultrasound (TVUS): Uterine dimensions, fibroid mapping, endometrial stripe measurement

• Pelvic MRI (with contrast if oncologic): Definitive fibroid/adenomyosis characterization, staging for malignancy, posterior compartment involvement in endometriosis

• Endometrial Biopsy (Pipelle or hysteroscopic): Mandatory in all cases of AUB to exclude endometrial carcinoma or hyperplasia

• Cervical Screening: Pap smear / HPV co-test within the preceding 3 years

• PET-CT Scan: Indicated when gynecologic malignancy with suspected nodal or distant disease is being evaluated

• Complete Blood Count (CBC) with iron studies: Assessment of anemia severity; may require pre-operative IV iron infusion or GnRH agonist to shrink fibroids and replete hemoglobin

• Renal Function Panel, LFTs, Coagulation Profile (PT/APTT/INR)

• 12-Lead ECG and 2D Echocardiogram (ECHO): For patients >40 years or with known cardiovascular risk factors (hypertension, diabetes, BMI >35)

• Chest X-Ray or CT Thorax (if malignancy suspected)

• Anesthesia fitness evaluation including airway assessment and pulmonary function if indicated

• CA-125, HE4, ROMA Score: If adnexal pathology or ovarian malignancy cannot be excluded

• RELATIVE AND ABSOLUTE CONTRAINDICATIONS:

• Active pelvic infection or untreated sexually transmitted infection (must be treated before surgery)

• Pregnancy

• Uncontrolled coagulopathy (e.g., INR >1.5 not correctable) or active anticoagulation that cannot be safely bridged

• Hemodynamically significant cardiac disease (EF <35%, recent MI within 6 months, severe aortic stenosis) — requires cardiology optimization first

• Extensive prior abdominal surgery with dense adhesions precluding safe pneumoperitoneum (relative contraindication; robotic platform may still be feasible with experienced surgeon)

• Bulky uterine/cervical malignancy with parametrial invasion (FIGO IIB+) or distant metastases — neoadjuvant chemoradiation preferred before surgical consideration

• Morbid obesity with BMI >55 in combination with severe obstructive sleep apnea — requires multidisciplinary pre-operative optimization

APPROACH 1 — TOTAL ROBOTIC HYSTERECTOMY (TRH) WITH DA VINCI XI SYSTEM (MOST COMMON):

The da Vinci Xi platform is the current generation system used in the majority of robotic gynecologic cases globally. The patient is positioned in dorsal lithotomy with steep Trendelenburg (25–30°). A 12 mm umbilical port is placed for the 3D endoscope; three 8 mm robotic instrument ports are placed in the lower abdomen; an additional 5–10 mm assistant port facilitates suction, irrigation, clip application, and specimen retrieval. The uterine manipulator (e.g., RUMI II or Koh Colpotomizer system) delineates the cervicovaginal junction, enabling precise colpotomy. Robotic instruments employed include monopolar curved scissors, bipolar Maryland forceps, vessel sealing devices (e.g., Intuitive's vessel sealer), and needle drivers. The surgical sequence involves: (1) development of vesicouterine space and bladder flap, (2) identification and isolation of bilateral ureters, (3) ligation of uterine vessels at their origin, (4) parametrial dissection, (5) colpotomy along the Koh ring, and (6) uterine removal vaginally with morcellation avoided in all cases of suspected or confirmed malignancy. Vaginal cuff closure is performed robotically using barbed suture (V-Loc or Stratafix 0-PDS) in a running locking fashion — a technically superior closure that reduces cuff dehiscence rates compared to laparoscopic technique.

APPROACH 2 — ROBOTIC RADICAL HYSTERECTOMY (TYPE III, PIVER-RUTLEDGE / QUERLEU-MORROW CLASS C):

For early-stage cervical cancer (FIGO IB1, select IB2) and endometrial carcinoma with cervical involvement, radical hysterectomy includes en-bloc removal of the uterus, cervix, upper 1–2 cm of vagina, cardinal and uterosacral ligaments (parametria), and bilateral pelvic lymph node dissection. The robotic platform is particularly advantageous here due to the need for precise parametrial dissection adjacent to the ureter's 'knee' and the internal iliac vasculature. Sentinel lymph node mapping using ICG (indocyanine green) fluorescence via the da Vinci FireFly imaging system has become standard practice at leading centers, reducing the morbidity of full pelvic lymphadenectomy in early-stage disease.

APPROACH 3 — ROBOTIC SUPRACERVICAL HYSTERECTOMY (RSH):

Appropriate for benign indications when the patient wishes to retain the cervix (and has normal cervical screening). The uterine corpus is amputated above the cervix. Tissue is morcellated inside a contained extraction bag (e.g., the Olympus Contained Tissue Extraction System or Lexion LARA bag) to eliminate the theoretical risk of dissemination of occult uterine malignancy — a practice mandated by FDA guidance since 2014. This approach has faster operative time but requires ongoing cervical surveillance.

APPROACH 4 — ROBOTIC HYSTERECTOMY WITH BILATERAL SALPINGO-OOPHORECTOMY (BSO) AND PELVIC/PARA-AORTIC LYMPH NODE DISSECTION:

Performed concurrently for endometrial carcinoma staging (per FIGO 2023 staging criteria) or high-grade ovarian malignancy. Robotic lymphadenectomy allows meticulous dissection along the external iliac, internal iliac, obturator, common iliac, and para-aortic chains with superior visualization of the genitofemoral nerve and obturator nerve, reducing neuropraxia rates compared to open or laparoscopic approaches.

APPROACH 5 — DA VINCI SP (SINGLE PORT) ROBOTIC HYSTERECTOMY:

Available at select premium centers in India (Apollo Hospitals, Fortis) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). A single 25 mm port placed at the umbilicus accommodates a flexible camera and three independently articulating instruments. This approach yields a virtually scar-free outcome and is gaining traction for patients with BMI <30 and uteri <14 weeks size.

COMPARISON — ROBOTIC vs. CONVENTIONAL LAPAROSCOPIC vs. OPEN ABDOMINAL HYSTERECTOMY:

• Open (Abdominal): Hospital stay 4–7 days; return to activity 6–8 weeks; highest blood loss (mean 300–500 mL); highest wound complication rate

• Conventional Total Laparoscopic Hysterectomy (TLH): Hospital stay 2–3 days; return 3–5 weeks; limited by 2D vision and fixed-axis instruments in complex anatomy

• Robotic (da Vinci): Hospital stay 1–3 days; return 2–4 weeks; blood loss <100 mL; superior in complex cases (large uteri, severe endometriosis, malignancy requiring lymphadenectomy); higher procedure cost offset by reduced complication-related hospitalization

PHASE 1 — PRE-TRAVEL PREPARATION (4–6 WEEKS BEFORE DEPARTURE):

• Submit medical records to GAF Healthcare's clinical team: operative notes, imaging (TVUS, MRI, PET-CT), biopsy pathology reports, recent blood work, and anesthesia history

• GAF Healthcare's partner gynecologic oncologist or robotic surgeon reviews case within 48–72 hours and issues a formal treatment plan with itemized cost estimate

• Obtain e-Medical Visa (India) or UAE entry visa with GAF Healthcare facilitation (typically processed within 3–5 business days)

• Pre-operative optimization at home: correction of anemia (IV iron infusion or oral iron supplementation), GnRH agonist therapy (leuprolide acetate 3.75 mg IM monthly × 2–3 months) if indicated to shrink fibroids and replenish hemoglobin, cessation of anticoagulants/NSAIDs as instructed

• Bowel preparation instructions and antibiotic prophylaxis protocol provided (e.g., single-dose IV cefazolin 2 g within 60 minutes of incision, or clindamycin if penicillin-allergic, per ACOG guidelines)

PHASE 2 — ARRIVAL AND PRE-OPERATIVE WORKUP (2–3 DAYS BEFORE SURGERY):

• GAF Healthcare team meets patient at airport; transfer to partnered hospital or serviced apartment

• Day 1: Hospital admission; comprehensive pre-operative workup completed in one day — CBC, CMP, coagulation, group and screen, 12-lead ECG, chest X-ray, anesthesia consultation, surgical consent

• Day 2: Pre-operative consultation with robotic surgeon; review of MRI/imaging; marking and surgical planning; pre-operative bowel prep if indicated; nil by mouth from midnight

PHASE 3 — OPERATIVE DAY:

• Procedure duration: 1.5–3.5 hours (simple benign hysterectomy) to 4–6 hours (radical hysterectomy with lymphadenectomy)

• General anesthesia with endotracheal intubation; arterial line placed for hemodynamic monitoring in complex/oncologic cases

• Intraoperative ureteral stent placement (temporary) considered in cases with severe endometriosis or anticipated parametrial involvement to facilitate ureteral identification

• Cell salvage not routinely used (blood loss typically minimal); crossmatch available as precaution

• Recovery room monitoring for 1–2 hours post-extubation; transferred to gynecology ward

PHASE 4 — IN-HOSPITAL RECOVERY (DAYS 1–3 POST-OPERATIVELY):

• Day 1 Post-Op: Early ambulation protocol begins within 4–6 hours of surgery (per ERAS — Enhanced Recovery After Surgery — gynecology protocol); urinary catheter removed at 24 hours; oral liquids and soft diet commenced; multimodal analgesia regimen (scheduled acetaminophen 1 g QID, ketorolac IV, low-dose opioid PRN, wound infiltration with liposomal bupivacaine)

• Day 2 Post-Op: Full oral diet; patient independently ambulatory; deep vein thrombosis (DVT) prophylaxis with LMWH (enoxaparin 40 mg SC daily) and pneumatic compression devices; vaginal cuff assessed

• Day 3 Post-Op: Discharge planning; wound check (port sites covered with Steri-Strips or glue); discharge medications prescribed (oral analgesics, iron supplementation, stool softeners, VTE prophylaxis for 4 weeks post-discharge with LMWH or rivaroxaban 10 mg OD as per oncologic protocols)

PHASE 5 — POST-DISCHARGE RECOVERY IN COUNTRY (DAYS 4–21):

• Patient stays in GAF Healthcare-partnered serviced apartment or hotel near the hospital

• Day 7: First post-operative review with surgeon — wound inspection, vaginal cuff healing assessment, pathology report discussion

• Day 14: Second post-operative review — confirm vaginal cuff integrity (critical milestone before air travel); assess for complications; final pathology discussed; adjuvant therapy planning initiated if oncologic case

• Activity restrictions: No heavy lifting (>5 kg) for 6 weeks; pelvic rest (no vaginal intercourse, tampons, or douching) for 8 weeks; driving restricted for 2–3 weeks; light walking encouraged from Day 1

• FIT-TO-FLY MILESTONE: Patients are typically cleared for international air travel at 14–21 days post-operatively, contingent on: intact vaginal cuff on clinical examination, no fever or signs of infection, adequate pain control on oral analgesics only, and ambulation without assistance. Extended-duration flights (>6 hours) require continued LMWH prophylaxis during travel per VTE prevention guidelines

PHASE 6 — LONG-TERM RECOVERY AT HOME (WEEKS 3–12):

• 6 weeks: Return to sedentary work; most patients report resolution of pre-operative symptoms (bleeding, pain, pressure)

• 8 weeks: Pelvic rest lifted; resumption of sexual activity; pelvic floor physiotherapy recommended post-BSO or if pelvic floor repair was concurrent

• 12 weeks: Full physical recovery; return to strenuous exercise

• If BSO performed: Hormone Replacement Therapy (HRT) discussion — transdermal estradiol (gel, patch) initiated at discharge if no estrogen-sensitive malignancy; reduces surgical menopause symptoms and long-term osteoporosis/cardiovascular risk

• Oncologic follow-up: GAF Healthcare coordinates with patient's home oncologist for adjuvant chemotherapy (carboplatin/paclitaxel for high-grade endometrial carcinoma) or radiation (vaginal brachytherapy for FIGO IA-IB endometrioid carcinoma) based on final histopathology and molecular profiling (MMR/MSI, POLE, p53 — per ESGO/ESTRO/ESP 2020/2023 risk stratification)